| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Theravance Biopharma Inc. | Telavancin | Bacteremia | Phase 3 | Trial Discontinued | Intravenous | Antibiotic |
| Theravance Biopharma Inc. | Ampreloxetine - (REDWOOD 0170) | Neurogenic orthostatic hypotension (nOH) | Phase 3 | Data Released | Oral | Neurology |
| Theravance Biopharma Inc. | YUPELRI (revefenacin) - (China trial) | Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Data Released | Inhalation | Respiratory |
| Theravance Biopharma Inc. | YUPELRI (revefenacin) - (PIFR-2) | Chronic obstructive pulmonary disease (COPD) | Phase 3 | Data Released | Inhalation | Respiratory |
| Theravance Biopharma Inc. | Izencitinib | Ulcerative Colitis | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| Theravance Biopharma Inc. | Velusetrag (TD-5108) | Gastroparesis | Phase 2b | Trial Discontinued | Oral | Gastroenterology |
| Theravance Biopharma Inc. | Nezulcitinib | Acute Lung Injury (ALI) caused by COVID-19 | Phase 2 | Trial Discontinued | Inhalation | COVID-19 |
| Theravance Biopharma Inc. | TD-8236 | Asthma | Phase 2 | Trial Discontinued | Inhalation | Respiratory |